The point is narrow and legal: Implementing Regulation (EU) 2026/1219 is a Commission authorising act, not another scientific “green light” and not a supplement authorisation. From 30 June 2026 one specific novel food — inulin-propionate ester — may be placed on the EU market after inclusion in the Union list, in two categories and under the annex maxima. There is no supplement category in the annex.
1. What exactly did the Commission authorise?
Document 32026R1219 (ELI: http://data.europa.eu/eli/reg_impl/2026/1219/oj; EUR-Lex: CELEX:32026R1219) — Implementing Regulation (EU) 2026/1219 of 9 June 2026 — authorises the placing on the market of inulin-propionate ester and amends Implementing Regulation (EU) 2017/2470. Published in OJ L, 2026/1219, 10.6.2026. Placing on the market of this novel food: from 30 June 2026 (date stated in the act; entry into force on the twentieth day after OJ publication aligns with that date).
Applicant: Imperial College Hammersmith Campus, DuCane Road, London W12 0NN, United Kingdom. Application filed on 14 February 2018; the Commission requested an EFSA opinion on 16 July 2018. The application sought use in cereal bars and fruit smoothies for the general population.
The NDA Panel, in Safety of inulin-propionate ester as a novel food pursuant to Regulation (EU) 2015/2283 (EFSA Journal 2025;23(7):e9534, DOI 10.2903/j.efsa.2025.9534, PubMed PMID 40708711), adopted on 25 June 2025, concluded that the NF is safe for the general population under the proposed conditions of use.
2. What EFSA established (e9534) — safety, not a claim
Per the NDA opinion: the substance is inulin (65–95% w/w) esterified with a propionic acid moiety (5–35% w/w); synthesised from inulin and propionic anhydride under alkaline conditions; not absorbed intact; metabolised mainly in the large intestine to inulin and propionate. Human studies (efficacy-oriented) up to 20 g/day for up to 12 months were generally well-tolerated (mild transient GI effects). The Panel: genotoxicity/subchronic studies were not required given physico-chemical properties, production, metabolic fate, the prior ANS assessment of propionic acid/salts (2014), and the large body of inulin data. Conclusion: safe for the general population under the proposed conditions of use.
EFSA opinion ≠ authorisation. Here — as with cRG-I and egg membrane hydrolysate — we have both layers: the safety assessment and the Commission act with a Union-list entry.
3. Categories and maxima (annex) — no supplements
The levels below come from Table 1 of the annex to Regulation 2026/1219. This is the full category scope in the act.
| Food category | Maximum level |
|---|---|
| Cereal bars | 17 g/100 g |
| Fruit smoothies | 3 g/100 ml |
Labelling designation: “inulin-propionate ester”.
4. Specifications — the Commission added parameters
Table 2 of the annex: white/off-white powder; inulin 65–95%; free propionic acid <1%; esterified propionate 5–35%; after hydrolysis 100–112%; N <0.1; fat <0.5; Na <0.1; As <0.1 mg/kg; Cd <0.01; Pb <0.05; Hg <0.05; TAC <1000 CFU/g; Listeria ND/25 g; E. coli <10; Enterobacteriaceae <10.
The Commission noted that composition/microbiological parameters from the EFSA opinion were not fully reflected in the proposed specifications — and added chemical and microbiological parameters to the specifications for safety.
5. Data protection until 30 Jun 2031
Under Articles 26 and 27 of Regulation (EU) 2015/2283 the Commission granted 5-year data protection. Beneficiary: Imperial College Hammersmith Campus. End date: 30 June 2031. Authorised from 30 June 2026.
Per the act’s recitals, protection covers inter alia batch-to-batch analyses (including quantification of inulin and propionate) and in-house analytical methods. A human trial was also claimed as proprietary, but recital (12) focuses the protection decision on batch analyses and methods.
During the protection period only Imperial College Hammersmith Campus may place this NF on the Union market, unless a subsequent applicant obtains authorisation without relying on the protected data or with agreement. This is procedural data protection, not an absolute exclusivity over “any inulin ester” outside this entry.
6. Novel-food authorisation ≠ health claim
Regulation 2026/1219 gives no basis for claims on satiety, glycaemia, microbiota or “propionate for metabolism”. Novel-food status does not automatically exclude all claims — but it is not itself a claim basis. Any such claim needs a separate basis under Regulation (EC) No 1924/2006.
7. Poland: GIS after EU authorisation
EU authorisation opens placing on the market of this NF in the Union under the list entry. A notification to the Chief Sanitary Inspector is not an additional novel-food authorisation. It is a separate duty when placing a specific product on the Polish market — and it does not create a supplement category absent from the EU annex.
The product must match the entry: designation “inulin-propionate ester”, bar/smoothie category, maxima 17 g/100 g or 3 g/100 ml, specification compliance. GIS does not “complete” novel-food authorisation.
8. Producer / importer checklist
- Confirm the act — 2026/1219 + entry in 2017/2470. Market from 30 Jun 2026. Not opinion-only.
- Name — “inulin-propionate ester”.
- Categories — only cereal bars ≤17 g/100 g and fruit smoothies ≤3 g/100 ml.
- Not a supplement — no supplement category in the annex; do not expand scope by marketing.
- Data protection — until 30 Jun 2031 Imperial College Hammersmith Campus; own authorisation possible on independent data or with agreement.
- Claim — the novel-food act does not give health claims.
- GIS (PL) — notification of a specific product, not a second novel-food authorisation.
Conclusion
Unlike recent EFSA opinions without a Commission act, inulin-propionate ester has a specific novel-food authorisation and a Union-list entry. The market for this entry opens from 30 June 2026, but it is narrow: two categories (bars and smoothies), maxima 17 g/100 g and 3 g/100 ml, no supplements in the annex, Imperial College data protection until 2031 and no automatic health claims. The honest message: safety authorisation opens lawful use of this ingredient under the list entry — it does not open a “metabolism” label and does not replace a GIS notification or a missing supplement category.
Primary sources
- Commission Implementing Regulation (EU) 2026/1219 — Document 32026R1219; ELI eli/reg_impl/2026/1219/oj; EUR-Lex eng. Authorisation of inulin-propionate ester and amendment of list 2017/2470; market from 30 Jun 2026; data protection until 30 Jun 2031.
- EFSA NDA Panel. Safety of inulin-propionate ester as a novel food… EFSA Journal 2025;23(7):e9534. DOI: 10.2903/j.efsa.2025.9534 — opinion of 25 Jun 2025; safety for the general population (PMID 40708711).
- Regulation (EU) 2015/2283 — novel foods; Arts 26/27 data protection.
- Implementing Regulation (EU) 2017/2470 — Union list of novel foods.
- Regulation (EC) No 1924/2006 — nutrition and health claims.